NASDAQ: ALXO
Alx Oncology Holdings Inc Stock Forecast, Predictions & Price Target

Analyst price target for ALXO

Based on 5 analysts offering 12 month price targets for Alx Oncology Holdings Inc

Min Forecast
$1.50+177.78%
Avg Forecast
$4.14+666.67%
Max Forecast
$9.00+1,566.67%

Should I buy or sell ALXO stock?

Based on 5 analysts offering ratings for Alx Oncology Holdings Inc.

Strong Buy
Strong Buy
3 analysts 60%
Buy
1 analysts 20%
Hold
1 analysts 20%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ALXO's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates ALXO as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their ALXO stock forecasts and price targets.

ALXO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-07
lockedlocked$00.00+00.00%2025-03-07
lockedlocked$00.00+00.00%2025-03-06
lockedlocked$00.00+00.00%2025-03-06Find Out Why
lockedlocked$00.00+00.00%2025-01-27

1 of 1

Forecast return on equity

Is ALXO forecast to generate an efficient return?

Company
-34.53%
Industry
142.9%
Market
80.27%
ALXO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ALXO forecast to generate an efficient return on assets?

Company
-26.55%
Industry
35.65%
ALXO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ALXO earnings per share forecast

What is ALXO's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$1.76
Avg 2 year Forecast
-$1.50
Avg 3 year Forecast
-$1.22

ALXO revenue forecast

What is ALXO's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$58.5M
Avg 2 year Forecast
$139.5M
Avg 3 year Forecast
$113.0M

ALXO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ALXO$0.54$4.14+666.67%Strong Buy
DOMH$4.59N/AN/A
GBIO$0.43$8.50+1,863.05%Strong Buy
ANVS$1.49$25.50+1,611.41%Strong Buy
PYPD$2.85$10.50+268.42%Buy

Alx Oncology Holdings Stock Forecast FAQ

Is Alx Oncology Holdings Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: ALXO) stock is to Strong Buy ALXO stock.

Out of 5 analysts, 3 (60%) are recommending ALXO as a Strong Buy, 1 (20%) are recommending ALXO as a Buy, 1 (20%) are recommending ALXO as a Hold, 0 (0%) are recommending ALXO as a Sell, and 0 (0%) are recommending ALXO as a Strong Sell.

If you're new to stock investing, here's how to buy Alx Oncology Holdings stock.

What is ALXO's earnings growth forecast for 2025-2027?

(NASDAQ: ALXO) Alx Oncology Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.96%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.59%.

Alx Oncology Holdings's earnings in 2025 is -$134,850,000.On average, 4 Wall Street analysts forecast ALXO's earnings for 2025 to be -$93,822,635, with the lowest ALXO earnings forecast at -$114,775,912, and the highest ALXO earnings forecast at -$72,068,596. On average, 3 Wall Street analysts forecast ALXO's earnings for 2026 to be -$80,252,385, with the lowest ALXO earnings forecast at -$106,234,449, and the highest ALXO earnings forecast at -$59,790,242.

In 2027, ALXO is forecast to generate -$64,861,736 in earnings, with the lowest earnings forecast at -$107,302,131 and the highest earnings forecast at -$22,421,341.

What is ALXO's revenue growth forecast for 2027-2029?

(NASDAQ: ALXO) Alx Oncology Holdings's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.

Alx Oncology Holdings's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast ALXO's revenue for 2027 to be $3,120,837,117, with the lowest ALXO revenue forecast at $3,120,837,117, and the highest ALXO revenue forecast at $3,120,837,117. On average, 1 Wall Street analysts forecast ALXO's revenue for 2028 to be $7,447,622,069, with the lowest ALXO revenue forecast at $7,447,622,069, and the highest ALXO revenue forecast at $7,447,622,069.

In 2029, ALXO is forecast to generate $6,031,607,623 in revenue, with the lowest revenue forecast at $797,559,126 and the highest revenue forecast at $11,265,656,119.

What is ALXO's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ALXO) forecast ROA is -26.55%, which is lower than the forecast US Biotechnology industry average of 35.65%.

What is ALXO's Price Target?

According to 5 Wall Street analysts that have issued a 1 year ALXO price target, the average ALXO price target is $4.14, with the highest ALXO stock price forecast at $9.00 and the lowest ALXO stock price forecast at $1.50.

On average, Wall Street analysts predict that Alx Oncology Holdings's share price could reach $4.14 by Mar 7, 2026. The average Alx Oncology Holdings stock price prediction forecasts a potential upside of 666.67% from the current ALXO share price of $0.54.

What is ALXO's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: ALXO) Alx Oncology Holdings's current Earnings Per Share (EPS) is -$2.58. On average, analysts forecast that ALXO's EPS will be -$1.76 for 2025, with the lowest EPS forecast at -$2.15, and the highest EPS forecast at -$1.35. On average, analysts forecast that ALXO's EPS will be -$1.50 for 2026, with the lowest EPS forecast at -$1.99, and the highest EPS forecast at -$1.12. In 2027, ALXO's EPS is forecast to hit -$1.22 (min: -$2.01, max: -$0.42).

What is ALXO's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ALXO) forecast ROE is -34.53%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.